TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00730717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humira
Description: Will receive 80 mg of Humira injection at week 0 followed by 40 mg weekly Humira injection from Week 1 to Week 23

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humira
Description: Will receive 40 mg Humira injection every other week from Week 0 to Week 23
Study: NCT04386304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (+)-Epicatechin
Description: (+)-Epicatechin is a synthetic flavanol
Study: NCT02427308

Intervention type: DRUG
Intervention: Miltefosine
Description: target dose = 2.5 mg/kg/day for 28 days
Study: NCT00894816

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus F19
Description: Infant cereals with the addition of Lactobacillus paracasei subsp. paracasei strain F19 (LF19)10E8 CFU per serving

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Infant cereals without any addition
Study: NCT02629718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NACT (Paclitaxel + Cisplatin or carboplatin)
Description: Paclitaxel 150mg/m2 over 3 hours + Cisplatin 70mg/m2 or carboplatin AUC = 6, repeat per 21 days, 3 cycles.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radical surgery
Description: Radical hysterectomy (Piver Type III or Type IV hysterectomy) plus bilateral pelvic lymph node dissection and para-aortic lymph node dissection or sampling

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radical surgery
Description: Radical hysterectomy (Piver Type III or Type IV hysterectomy) plus bilateral pelvic lymph node dissection and para-aortic lymph node dissection or sampling
Study: NCT01334177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLR8 agonist VTX-2337
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacogenomic studies
Description: Correlative studies
Study: NCT02113982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tagraxofusp

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tagraxofusp

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tagraxofusp
Study: NCT01761968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: givinostat
Description: Patients will continue at their last tolerable dose and treatment schedule of givinostat monotherapy. Givinostat is a histone-deacetylases inhibitor. The product will be supplied as hard gelatine capsules for oral administration at the strength of 50 mg, 75 mg and/or 100 mg each.~If patients previously received givinostat in combination with other drugs during a core protocol or a compassionate use program, they will be treated at their last tolerable dose of this combination.
Study: NCT03585881

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3DPrinted Windowed Bracket- Positioning tray
Description: 3 D printed tray with windows for accurate positioning of brackets
Study: NCT02432378

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cisplatin + celecoxib + DC vaccine
Description: Cisplatin 50 mg/m2 by IP once per cycle (21 days) + celecoxib daily 200 mg by mouth daily + intranodal vaccine injections once per cycle
Study: NCT00427895

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine (13vPnC)
Description: 0.5 mL dose administered on day 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine (13vPnC)
Description: 0.5 mL dose administered 3-4 years after dose 1

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 23-valent Pneumococcal Polysaccharide Vaccine (23vPS)
Description: 0.5 mL dose administered 3-4 years after dose 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine (13vPnC)
Description: 0.5 mL dose administered 3-4 years after dose 1
Study: NCT02432378

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cisplatin + CKM + Celecoxib + DC Vaccine
Description: Cisplatin 50 mg/m2 by IP once per cycle (21 days) + celecoxib daily 200 mg by mouth daily + IFN by IP once per cycle + rintatolimod 200 mg by IP once per cycle + intranodal vaccine injections once per cycle
Study: NCT04023669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prexasertib
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prexasertib
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given subcutaneously (SQ). Alternatively, pegfilgrastim may be given.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given subcutaneously (SQ). Alternatively, pegfilgrastim may be given.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: peg-filgrastim
Description: Given subcutaneously (SQ). Alternatively, filgrastim may be given.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: peg-filgrastim
Description: Given subcutaneously (SQ). Alternatively, filgrastim may be given.
Study: NCT04074720

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Tissue Sample collection
Description: Tissue sample collected following standard of care procedure patient was already scheduled to have

Intervention type: OTHER
Group type: OTHER
Intervention: Blood Sample Collection
Description: A one time sample of blood will be collected on day of standard of care procedure

Intervention type: OTHER
Group type: OTHER
Intervention: Rectal Swab
Description: optional rectal swab may be collected on day of standard of care procedure
Study: NCT02102646

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triptorelin
Description: Androgen deprivation therapy by Pamorelin 22,5mg/24 weeks administered intramuscularly.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Orchiectomy
Description: Androgen deprivation therapy by bilateral subcapsular orchiectomy
Study: NCT02314468

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Negative pressure wound therapy
Description: NPWT changed twice a week.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Glycerol Preserved Allografts (GPA)
Description: GPA changed every 7 to 10 days.
Study: NCT04861103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovenox
Description: Three times a day dosing and measuring Xa peak and trough levels
Study: NCT01213160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4547
Description: film coated tablet, PO, twice daily
Study: NCT03050255

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical air

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical air

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical air
Study: NCT00524511

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgical skin staples
Description: Standard method to close abdominal surgical wounds

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dermabond
Description: Alternative method (superglue) to close abdominal surgical wounds
Study: NCT03910634

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluorouracil
Description: 1.33g/body surface QW1, continuous intravenous infusion for 72 hours, repeated for 4 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity modulated radiation therapy
Description: Radiotherapy for 5-6 weeks，50-60Gy

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Intensity modulated radiation therapy
Description: Radiotherapy for 5-6 weeks，50-60Gy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Carboplatin (AUC 2), QW1, intravenous drip, repeat for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: carboplatin
Description: Carboplatin (AUC 2), QW1, intravenous drip, repeat for 4 weeks
Study: NCT03464734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab and Nanoparticle Albumin-bound Paclitaxel
Description: At study entry, patients will receive 2 cycles of pembrolizumab at the dose of 200 mg, intravenously in 30 min, on day 1 and nab-paclitaxel 125 mg/m2 intravenously in 30-40 min, on day 1 and 8.
Study: NCT00579215

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhance Care
Description: EC will receive a decision aid with seven components: social support, anticipatory guidance, adhering to the patient's preference for participation in treatment decision making, a quality decision-making process tutorial, normalization (using a CD program), structured time with oncology professionals to discuss difficult decisions, and values clarification of 3 decisions throughout treatment. Self-report measures will be used for all participants in addition to probes for the taped interviews with EC. The outcome measures are quality decision making and decisional conflict. Two panels (decision making and lung cancer) will review the protocol twice. The plan will include serially screening the appointment roster. The decision aid will be administered during three clinic visits

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual Care
Description: As an intentional control, the usual care group will receive standard care related to lung cancer and treatment; they will not receive any oral, written, or recorded information related to decision making. Usual care includes anticipatory guidance related to the disease and treatment (e.g., what to do about treatment side effects, signs of an infection, why a treatment would be changed or stopped) using patient education materials normally used in the MSKCC, TOS, Outpatient Clinic.
Study: NCT02472821

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interactive youth educational program
Description: Participation in a community-based face-to-face interactive youth educational program focusing on hearing health (i.e., noise hazards, risk of noise-induced hearing loss, mechanism of injury to the internal ear, and preventive measures)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interactive youth educational program
Description: Participation in a community-based face-to-face interactive youth educational program focusing on hearing health (i.e., noise hazards, risk of noise-induced hearing loss, mechanism of injury to the internal ear, and preventive measures)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet-based educational booster
Description: Visit to an educational Web site focused on hearing health
Study: NCT01592734

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene glycol with electrolytes
Description: Constipation treatment: 1-4 sachets/day according to the patient age. 1 sachet contains 6.9 g PEG-EL. Treatment period: 4 weeks.~Faecal impaction resolution: 4 sachets as initial dose and increasing 2 sachets a day until resolution or up to 7 days.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol
Description: Constipation: 0.7 g/kg/day in 2 divided doses for children of less than 20 kg. For children \> 20 kg the daily dose was up to PEG 30 g daily. Treatment period: 4 weeks.~Faecal impaction resolution: 1.5 g/kg/day in 2 doses until resolution or up to 6 days.
Study: NCT03715114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GV-971
Description: Oral GV-971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GV-971
Description: Oral GV-971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GV-971
Description: Oral GV-971

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Placebo
Study: NCT02992288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neladenoson bialanate (BAY1067197)
Description: 5 mg orally once daily for 20 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neladenoson bialanate (BAY1067197)
Description: 10 mg orally once daily for 20 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neladenoson bialanate (BAY1067197)
Description: 20 mg orally once daily for 20 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neladenoson bialanate (BAY1067197)
Description: 30 mg orally once daily for 20 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neladenoson bialanate (BAY1067197)
Description: 40 mg orally once daily for 20 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Orally once daily for 20 weeks
Study: NCT03398317

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PICSI
Description: sperm selection using PICSI dish for selecting sperm with lower DNA fragmentation index

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MACS
Description: sperm selection using MACS for selecting sperm with lower DNA fragmentation index
Study: NCT03050255

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical air

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical air

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical air

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen (2Liter/min)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen (2Liter/min)
Study: NCT04636125

Intervention type: DRUG
Group type: OTHER
Intervention: Doxycycline 100 MG Oral Tablet
Description: Patients that are undergoing a single stage revision total shoulder arthroplasty will be enrolled in this study. As is standard of care, routine cultures will be taken from predetermined areas in the shoulder. All patients will be treated with 13 days of oral Doxycycline pending culture results.
Study: NCT03576586

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief computerized intervention
Description: Brief computerized intervention (computer game Tetris) plus usual care in the maternity department

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention placebo control
Description: Brief cognitive task plus usual care in the maternity department
Study: NCT02856568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ricolinostat
Description: Given PO
Study: NCT04558125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNKase
Description: Tenecteplase (0.25 mg/kg) supplied by Genentech, Inc. as a sterile, lyophilized powder, diluted with 10mL sterile water.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo to match supplied by Genentech, Inc. as a sterile, lyophilized powder, diluted with 10mL sterile water.
Study: NCT03050255

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen (2Liter/min)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen (2Liter/min)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen (2Liter/min)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen (2Liter/min)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen (4Liter/min)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen (4Liter/min)
Study: NCT04558125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: All participants must also receive standard of care anticoagulation therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: All participants must also receive standard of care anticoagulation therapy.
Study: NCT00430014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atiprimod
Description: Starting Dose of 60 mg/day orally for 14 days of 28 day cycle.
Study: NCT01328886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: omalizumab lyophilized 150 mg injection
Study: NCT03050255

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen (4Liter/min)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen (4Liter/min)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen (4Liter/min)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen (4Liter/min)
Study: NCT00971243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-513 Lowest Dose and Metformin
Description: MP-513 tablets, once a day and Metformin tablets, for 24 weeks and extension treatment for up to 52 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-513 Low Dose and Metformin
Description: MP-513 tablets, once a day and Metformin tablets, for 24 weeks and extension treatment for up to 52 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-513 Medium Dose and Metformin
Description: MP-513 tablets, once a day and Metformin tablets, for 24 weeks and extension treatment for up to 52 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-513 High Dose and Metformin
Description: MP-513 tablets, once a day and Metformin tablets, for 24 weeks and extension treatment for up to 52 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo and Metformin
Description: Placebo tablets once a day, and Metformin tablets, for 24 weeks and extension treatment for up to 52 weeks.
Study: NCT02953860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant with Enzalutamide
Description: 500mg of Fulvestrant will be given IM on days 1, 15, 28, then every 4 weeks as per standard of care (SOC) and 160mg of Enzalutamide will be given PO daily. Patients will receive a tumor biopsy at the start of treatment and 4 weeks after the start of treatment, with an optional 3rd biopsy at the end treatment.
Study: NCT03044925

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote magnetic navigation
Description: Pulmonary vein isolation and other areas ablation guided by remote magnetic navigation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cryoablation
Description: Pulmonary vein isolation and other areas ablation used by cryoballoon
Study: NCT02817022

Intervention type: OTHER
Group type: OTHER
Intervention: developmentally supportive care
Description: DSC components will be strictly emphasized on protected sleep, pain and stress assessment and management, activities of daily living (positioning, feeding and skin care), the healing environment
Study: NCT03020654

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual environment with fast moving objects
Description: A beach/park environment with graded moving objects, the individual will complete head and eye exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual environment with no movement
Description: A beach/park environment with static objects, the individual will complete head and eye exercises.
Study: NCT02769559

Intervention type: PROCEDURE
Intervention: Reduction mammaplasty
Description: Surgical removal of excess breast tissue
Study: NCT01005459

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetracaine
Description: Tetracaine 2mg will be combined with Fentanyl 20 mcg and Epinephrine 50 mcg to treat labor pain.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Bupivacaine 2 mg combined with fentanyl 20 mcg and Epinephrine 50 mcg will be used to treat labor pain.
Study: NCT03998982

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycyrrhetinic Acid
Description: Compound glycyrrhizin tablets 75 mg three times per day, 1 month

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: HD-DXM (orally at 40 mg daily for 4d)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: HD-DXM (orally at 40 mg daily for 4d)
Study: NCT01292486

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectra Optia Apheresis System
Description: In this study, the safety and effectiveness of the new device will be assessed in two ways. First, MNC collections in growth-factor mobilized cancer patients will be evaluated to confirm that the Spectra Optia is able to collect stem cells. Second, following stem-cell collection and transplant, the number of days required for the collected hematopoetic stem cells to engraft/recover will be compared with historical COBE Spectra engraftment/recovery data.
Study: NCT00685412

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VGX-3100
Description: DNA plasmid delivered via IM injection + electroporation using CELLECTRA device

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VGX-3100
Description: DNA plasmid delivered via IM injection + electroporation using CELLECTRA device

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VGX-3100
Description: DNA plasmid delivered via IM injection + electroporation using CELLECTRA device
Study: NCT04172181

Intervention type: PROCEDURE
Intervention: cord blood stem cell transplantation
Description: Unrelated cord blood stem cell selection； Reduced intensity conditioning； GVHD prevention； Infection prevention.
Study: NCT02264730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ClotFoam
Description: Patient has not received blood products between screenings
Study: NCT06052579

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: new hand-held retractor systems-assisted WiltseTLIF surgery
Description: patients were included in study group underwent the new hand-held retractors assisted Wiltse TLIF surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: new hand-held retractor systems-assisted WiltseTLIF surgery
Description: patients were included in study group underwent the new hand-held retractors assisted Wiltse TLIF surgery
Study: NCT02835378

Intervention type: OTHER
Intervention: No intervention
Study: NCT02496286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intraperitoneal Bevacizumab
Description: Bevacizumab 200mg diluted in 250 ml of normal saline
Study: NCT02689427

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Axillary Lymph Node Dissection
Description: Undergo axillary lymph node dissection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymph Node Biopsy
Description: Undergo lymph node biopsy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgical resection of primary tumor